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Introduction: Langerhans cell histiocytosis is a rare disease within the adult population, with very few cases
reported as solitary hypophyseal lesions in adults. Of the reported cases, most have been treated successfully with
surgery, radiotherapy, and/or chemotherapy. Radiotherapy has been thought to be curative at the relatively low
dose of 20Gy. Here we report a case of recurrent hypophyseal Langerhans cell histiocytosis 9 months after
radiotherapy with an interval period of symptomatic and radiographic response to therapy.
Case presentation: A 50-year-old Caucasian woman who had headaches, memory difficulties, and diabetes
insipidus was found to have a 2.5cm suprasellar mass. Langerhans cell histiocytosis was diagnosed following
stereotactic brain biopsy. Further workup revealed no other lesions. Initial radiation treatment succeeded in
shrinking the tumor and relieving clinical symptoms temporarily; however, growth and recurrence of clinical
symptoms was noted at 9 months. Re-irradiation was well tolerated and the patient had no acute side effects.
Conclusion: Isolated hypophyseal involvement by Langerhans cell histiocytosis in adults is a unique presentation of
a rare disease. Although radiotherapy doses as low as 20Gy have been reported to offer control, this case
demonstrates that higher doses may be warranted to ensure tumor control. With modern imaging and
radiotherapy techniques higher doses should offer little increased more durable risk to surrounding critical
structures.Introduction
Langerhans cell histiocytosis (LCH) is a rare disorder of
antigen-presenting cells derived from the bone marrow
that are termed ‘Langerhans cells’ in honor of their dis-
covery by Paul Langerhans. The disease is believed to
have first been reported in 1865 and has been known
by many different names [1]. Early descriptions of dis-
ease in children with exophthalmos, lesions of skull
bones, and diabetes insipidus (DI), led to the designa-
tion ‘Hand–Schüller–Christian disease’. Following the
conceptualization of the reticuloendothelial system,
patients with related disease that included hepatomeg-
aly, splenomegaly, lymphadenopathy, and macrophage
hyperplasia of various organs (among other symptoms)
were known to have ‘Letterer–Siwe disease’. Reports of* Correspondence: jjaboin@radonc.wustl.edu
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reproduction in any medium, provided the orisolated ostotic lesions with prominent histiocytes have
been referred to as ‘eosinophilic granulomas’ and ‘soli-
tary granulomas of the bone.’ Isolated involvement of
the hypothalamus was termed ‘Gagel’s granuloma’ [2].
In 1953, Lichtenstein unified these diseases as ‘Histiocy-
tosis X’ with emphasis on patterns of clinical involve-
ment. Subsequent electron microscopic characterization
of Langerhans cells with the recognition of ‘Birbeck
granules’ as their signature identifying feature, led to
the eventual use of the current all-inclusive term LCH.
Although LCH is more common and best character-
ized in children, the disorder also presents in adults. It
has an estimated incidence of 1 to 2 cases per million
per year in adults with peak incidence at 33 years of
age [3]. Clinical symptoms are related to the site of
disease. Commonly affected organs include the lungs,
skin, and bone; however, virtually any tissue may be
involved, including the stomach, central nervous sys-
tem, thyroid, and liver. Patterns of involvement are
classified as single system, single system multifocal,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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comes are observed in older patients and patients with
single system disease; worse outcomes are observed in
multisystem disease, in patients with organ dysfunc-
tion, in isolated pulmonary disease, and in younger
patients [3]. Multisystem disease can be further classi-
fied as low risk or high risk (hematopoietic system,
lungs, liver, and spleen) based on involvement of spe-
cific organs [4].
Endocrine abnormalities are relatively common in
LCH multisystem disease. In one study, 81 of 188
(43.1%) adult patients with multisystem disease devel-
oped DI [3]. In the same study, no patient with single
system disease developed DI. Hypothyroidism was also
noted in 18 (9.6%) patients with multisystem disease and
in no patients with single system disease. It is unclear
whether these abnormalities in this series were attribut-
able to pituitary and/or hypothalamic lesions or to com-
pression of the pituitary stalk by nearby osseous lesions.
The ‘gold standard’ for histopathologic diagnosis is the
presence of characteristic Birbeck granules on electron
microscopy [5]. Other histologic features seen in LCH
lesions include detection of CD1a, CD207, S100 protein,
adenosine triphosphate (ATP)ase, or alpha-D-mannosidase
on the cell surface [3]. In practice, the presence of CD1a
and S100 on histiocytes is thought to be highly specific
for LCH [6,7].
We present a case of isolated hypophyseal histiocytosis
in a 50-year-old woman complicated by recurrence 9
months after initial radiation therapy. It rarely presents
as an isolated lesion of the hypophysis. Of the previously
reported cases we found in the literature, six were suc-
cessfully treated with radiation therapy. This case was
complicated by an early recurrence, suggesting that
these tumors may require higher initial radiation doses,
at least in adult presentations, to ensure good local
control.
Case presentation
A 50-year-old right-handed previously healthy Caucasian
woman presented with a several month history of daily
headaches, blurry vision, worsening daytime somno-
lence, and progressive memory difficulties. These symp-
toms had a significant impact on her activities of daily
living and finally resulted in loss of employment. During
this time she reported sleeping between 12 and 14 hours
per day without improvement in energy level and had
gained 18kg (40 pounds) in weight. She also reported a
constant feeling of thirst, polydipsia (drinking 10 liters of
fluid daily), polyuria, and nocturia. She had been ame-
norrheic for 5 years and reported no recent vaginal
bleeding. She denied nausea, vomiting, heat or cold in-
tolerance, and galactorrhea. Her past medical history
was significant only for medication-controlledhypertension and she had no family history of endocrine
abnormalities. Her physical examination was significant
for bilateral peripheral visual field loss. The remainder of
the examination, including a thorough neurological
examination, was unremarkable. Laboratory studies
demonstrated panhypopituitarism as follows (normal
range in parentheses): thyroid-stimulating hormone
1.8uIU/mL (0.35–5.50), free thyroxine 0.52ng/dL (0.90–
1.80), prolactin 42ng/mL (2.8–29.0), luteinizing hormone
<1IU/L (postmenopausal range 15.9–54.0), follicle-
stimulating hormone 2.1IU/L (23.0–116.3), adrenocorti-
cotropic hormone 19pg/mL (0–49), insulin-like growth
factor 38ng/mL (100–250), and cortisol at 4:00 p.m.
<1.5mcg/dL (4.3–22.4).
A magnetic resonance image (MRI) of the patient’s
brain with contrast showed a 25 × 22 × 20mm intensely
enhancing suprasellar mass involving the hypothalamus
and optic chiasm. The mass appeared to be separate
from the pituitary on both sagittal and coronal imaging
(Figure 1). Differential diagnosis included a metastatic
lesion, as well as primary lesions such as central nervous
system lymphoma, chordoma of the pituitary stalk, gli-
oma, germinoma, sarcoidosis, and LCH. Computed tom-
ography (CT) imaging of her chest, abdomen, and pelvis
with contrast showed no evidence of neoplastic disease.
Angiography revealed only mild displacement of the
thalamic perforating arteries due to mass effect, and
minimal tumor vascularity.
A stereotactic needle biopsy of the mass was per-
formed. A histological examination showed mildly gliotic
brain parenchyma with a weakly angiocentric lympho-
plasmacytic infiltrate that ranged from modest to in-
tense. Also present were a few aggregates of histiocytes,
one resembling a well-formed non-necrotizing granu-
loma (Figure 2A). Close inspection of these histiocytes
revealed notched or grooved nuclei and abundant pale
granular eosinophilic cytoplasm (Figure 2B). No atypical
lymphocytes, no multinucleated giant cells, no infectious
organisms or viral inclusions, and only rare eosinophils
were identified. The histological differential diagnosis
included: lymphoma, lymphocytic hypophysitis, and
LCH. Immunohistochemical staining showed a mixed
population of T-cells (Figure 2C) and B-cells (Figure 2D)
with a normal 2:1 ratio of kappa- and lambda-light chain
expression (Figure 2E and 2F), consistent with a reactive
non-neoplastic infiltrate. Further characterization of the
histiocytes showed strong reactivity for S100, CD163,
and CD1a (Figure 3), supporting the diagnosis of LCH.
Prednisone and replacement hormone therapy,
initiated immediately after her initial diagnosis, signifi-
cantly improved the patient’s functional status; however,
she remained fatigued and did not remember her initial
hospital visits. Her case was presented at our multidiscip-
linary Tumor board. The consensus was that radiation
Figure 1 Radiographic imaging at the time of initial diagnosis. T1-weighted magnetic resonance image with (A, B, and C) and without (D)
contrast demonstrate the large enhancing Langerhans cell histiocytosis lesion in the suprasellar region. Fluid attenuated inversion recovery (E)
and T2-weighted imaging (F) demonstrate mild edema in the surrounding deep thalamic nuclei and brainstem.
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of her tumor. She underwent CT simulation for radiation
therapy planning. A 4-field 3D-conformal plan was gen-
erated with a prescription dose of 20Gy in 10 once-daily
fractions. She completed radiation therapy with no acute
complications.
At 3 months post-radiotherapy, she reported her en-
ergy level and cognition had significantly improved on
endocrine therapy and at 5 months post-radiotherapy,
an MRI demonstrated a marked decrease in the lesion
size (8mm greatest dimension) with decreased edema in
surrounding tissues as seen on fluid attenuated inversion
recovery (FLAIR) imaging. At 9 months post-radiother-
apy, she presented with a 2-week history of mild confu-
sion, forgetfulness, increased fatigue, and an increase in
weight. She has had routine follow-up visits with her
endocrinologist with no recent changes in her endocrine
replacement regimen. MRI at this time demonstrated an
interval increase in lesion size from 8mm to 14mm and
increased edema in the surrounding tissues.
Her case was presented at our multidisciplinary
Neuro-Oncology Tumor board. Because she initially
responded well to radiation therapy, a second course of
radiation was recommended. She was re-simulated and
treated with an additional 30Gy in 15 once-daily frac-
tions. She completed radiotherapy with only mildfatigue. At the completion of treatment, she reported
improvement in her vision and was able to reduce her
steroid dose. Three months after completion of her sec-
ond course of radiotherapy, an MRI demonstrated a de-
crease in size of the mass to 10mm with resolution of
surrounding FLAIR signal, representing a favorable re-
sponse to her second course of radiotherapy.
Discussion
Overall, LCH is a rare disease in adults. As such, there is
a paucity of data available to guide treatment of adult
LCH. Depending on disease site and symptoms, therapy
may include chemotherapy, immune modulation, radi-
ation therapy or observation. An ongoing trial evaluating
chemotherapy is being conducted by the Histiocyte Soci-
ety (trial LCH-A1), but results have yet to be published.
In 2003 the Histiocyte Society published a retrospective
analysis of 274 adults in 13 countries with LCH [3].
Chemotherapy, most often vinblastine with or without
steroids, was the initial treatment in 138 patients. Im-
munotherapy with prednisone or cyclosporine (n = 21)
or observation (n = 110) were also initial therapeutic
options. There was no reported analysis of outcomes
based on chosen treatment modality. Another group
reported results of seven patients treated with MACOP-
B (methotrexate, arabinofuranosyl cytidine [cytarabine],
Figure 2 Histological images of suprasellar stereotactic brain biopsy specimen. Hematoxylin and eosin stained sections (A and B) show
gliotic brain parenchyma with diffuse involvement by plasma cells, lymphocytes, and foci of histiocytes (A); high magnification of histiocytic
aggregate shows cells with pale granular eosinophilic cytoplasm and grooved nuclei, indicated by arrows (B). Sections stained
immunohistochemically for CD3 (C) and CD20 (D) show both T-cells and B-cells, respectively, within the lymphocytic infiltrates. In situ
hybridization against kappa-light chain messenger ribonucleic acid (E) and lambda-light chain messenger ribonucleic acid (F) reveals a normal
ratio of kappa-light chain to lambda-light chain expression. All histology images were captured using the following equipment: Olympus BX51
microscope, Olympus DP70 camera, and Olympus DP controller software. There was no image manipulation and scale bars were added in
Photoshop, modeled over calibrated DP controller scale bars (not shown).
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and bleomycin), a chemotherapy regimen used for ag-
gressive lymphoma [8]. All patients showed a response;
complete response (CR) was observed in five patients.
CR was maintained for 2 patients at a median follow-up
of 6.5 years. Relapse was observed in the other patients
at 5, 8, and 62 months. In children, a study of 170 single
system (e.g. low-risk) LCH patients showed that 81%
of patients were disease free after initial therapy [9].
A second pediatric trial of 143 multisystem (e.g. high-
risk) LCH patients were randomized to vinblastine or
etoposide for 24 weeks with a single initial dose ofcorticosteroids [10]. Response was equivalent (76% and
83% 3-year-survival respectively). Demographic para-
meters known to be correlated with improved survival
included: age >2 years; fewer involved organs; and
response at 6 weeks.
To date, only six cases of isolated pituitary lesions in
adults treated with radiotherapy have been described in
the literature [11-19]. The five most recent cases were
treated with 20Gy in 10 fractions (three patients)
[15,16], 21Gy in 15 fractions (one patient) [11], 21Gy
with the addition of chemotherapy (one patient) [19], or
radiosurgery (one patient) [17]. Fractionated treatment
Figure 3 Histological characterization of histiocytic cells.
Sections stained immunohistochemically show diffuse reactivity
within histiocytes for S100 (A) and monocyte and macrophage
marker CD163 (B), and a membranous staining pattern for CD1a (C).
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reported follow-up ranging from 1 to 8 years; no failures
have been reported to date. The patient treated with
radiosurgery experienced recurrence approximately 1
year after treatment. His recurrence was successfully
controlled with vinblastine, cyclophosphamide and pred-
nisone. For the patient in our report, a dose of 30Gy wasselected. We wished to take the lesion to a cumulative
radiation dose below the threshold for radiation-induced
toxicity to the optic nerves and chiasm, but significantly
higher than that received in her prior course of radio-
therapy. The increased fraction number, higher dose and
smaller initial lesion size would suggest a greater chance
of control from a radiobiological standpoint.
There are reports suggesting the use of chemotherapy
as a first-line treatment for these patients [18,19]. This
treatment strategy was discussed both on initial presenta-
tion and at the time of recurrence in this case. At the
time of initial diagnosis, it was felt that local therapy
could offer a durable response with minimal risk of side
effects from radiotherapy while reserving chemotherapy
for treatment of systemic disease, if it were to arise. At
the time of recurrence, the use of chemotherapy was
revisited. Based on the initial good response of the tumor
to fractionated therapy and the lack of any systemic dis-
ease, a second course of radiation was prescribed. As
chemotherapeutic agents commonly used to treat LCH
(vinca alkaloids, antimetabolites, and antifolates) are
often associated with significant side effects, it was felt
chemotherapy would be reserved for salvage therapy
when either surrounding normal tissues would not toler-
ate re-irradiation or if systemic disease were to arise. Re-
irradiation of any site is more technically challenging and
may carry increased risk of adverse side effects compared
to initial therapy. The fact that the patient was re-treated
at the same institution using modern CT simulation
techniques mitigated some technical difficulties and
allowed us to calculate composite dose distributions, thus
enabling us to ensure that critical structures were spared.
The QUANTEC (Quantitative Analyses of Normal Tis-
sue Effects in the Clinic) data analysis on radiation-
induced toxicities was used to evaluate risk to critical
structures based on the composite plan. All parameters
were well within the minimal risk parameters. Specific-
ally, radiation doses less than 60Gy in 2Gy fractions to
the optic nerves and chiasm have a very low rate of
radiation-induced optic neuritis [20]. The optic chiasm
was adjacent to the radiation field and received a total
(composite) mean dose of 51.43Gy (total max dose
52.10Gy). The optic nerves received slightly lower mean
doses than the chiasm in the composite plan, 13.53 and
9.36, and lower maximum point doses, 48.94Gy and
43.76Gy, for the left and right respectively. The brain and
brainstem were also well within the allowed limits for
minimal risk with median composite doses of 12.34 and
32.42, and maximum composite doses of 52.25Gy and
52.09Gy, respectively [21,22].
Conclusion
This case demonstrates a rare presentation of a rare dis-
ease. Although a handful of cases involving LCH limited
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represents only the second example of recurrence after
radiation therapy. Given the location of this disease, a
higher initial radiotherapy dose may be justified because
this will probably reduce the chance of failure in a re-
gion of the brain surrounded by multiple critical struc-
tures. Higher radiotherapy doses are easily achievable in
this region using modern radiotherapy techniques that
maintain minimal risk of radiation-related toxicities.
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